ZVRA

AI Memo

Zevra Therapeutics

As of 2026-10-18/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

EU arimoclomol re-examination • 2026-12-31

Base target: $10 / p=45% prob

Biggest risk

The prior negative CHMP opinion, modest Q2 new-enrollment count and slow event accumulation in DiSCOVER make forward outcomes uncertain. No verified subsequent analyst revisions are available in the packet. [#SEC-8K-2026-08-05]

Invalidation

Break below $7 or thesis failure.

What would change my mind?

MIPLYFFA-led growth could continue, supported by Q2 revenue of $39.7 million, including $30.2 million from U.S. MIPLYFFA, and $260.2 million in cash and investments at June 30. A favorable EU re-examination would add upside. [#SEC-8K-2026-08-05]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

$10

p=45%

Bull target

$14

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Celiprolol development path
MIPLYFFA commercial uptake
MIPLYFFA-led growth could continue, supported by Q2 revenue of $39.7 million, including $30.2 million from U.S.

BearKey bullets

Another negative EU opinion could delay or prevent arimoclomol approval there.
[#8-K-2026-08-05]
DiSCOVER is event-driven and had only three confirmed events at June 30, limiting readout timing visibility.

WatchKey bullets

EU arimoclomol re-examination

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $10 (p=45%)

Target spread vs base: +40% / -35%

Scenario probabilities

Bull Target: $14 (p=30%)Base Target: $10 (p=45%)Bear Target: $7 (p=25%)

Commentary

The official August earnings exhibit supports improved commercial execution, while the EU setback remains material. The packet does not verify a post-release price reaction or subsequent analyst revisions. Zero sentiment metrics denote unavailable data, not neutral readings; social coverage is insufficient. The positive deterministic prior is tempered by low coverage and uncertain forward milestones.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Celiprolol development path
MIPLYFFA commercial uptake

Scenarios

Bull Target (Scenario probability)

$14 / p=30% prob

Base Target (Scenario probability)

$10 / p=45% prob

Bear Target (Scenario probability)

$7 / p=25% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
EU arimoclomol re-examination
Zevra requested re-examination after a negative CHMP opinion on its NPC application. A reversal could expand the commercial opportunity; another negative opinion would extend the setback. A fourth-quarter outcome is an estimate, not a confirmed decision date. [#8-K-2026-08-05] [#SEC-8K-2026-08-05]
Prob 40.00% • Move 20.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Celiprolol development path
2026-12-31
Zevra expected FDA engagement in the second half of 2026 about accelerating its event-driven Phase 3 DiSCOVER trial. At June 30, 66 patients were enrolled and only three events confirmed; a faster path remains unestablished. [#SEC-8K-2026-08-05]
Prob 35% • Move 10% • Priced-in 20%
MIPLYFFA commercial uptake
2027-03-31
Q2 U.S. MIPLYFFA revenue reached $30.2 million, but only 14 new prescription enrollment forms brought the launch-to-date total to 184. Sustained sales growth and stronger enrollment would support the thesis; slowing uptake would weaken it. [#SEC-8K-2026-08-05]
Prob 60% • Move 16% • Priced-in 55%

Risks

Another negative EU opinion could delay or prevent arimoclomol approval there. [#8-K-2026-08-05]
DiSCOVER is event-driven and had only three confirmed events at June 30, limiting readout timing visibility. [#SEC-8K-2026-08-05]
MIPLYFFA concentration and only 14 new Q2 prescription enrollment forms leave commercial-growth durability uncertain. [#SEC-8K-2026-08-05]
The packet does not establish current analyst revisions, a post-release price reaction, or a directly comparable peer set.

Peers

Symbol	Summary
IRWD	Similar market capitalization and a commercial pharmaceutical business, but a different therapeutic area; only a loose valuation comparison.
AVTX	Similar market capitalization, but its development-stage profile is not directly comparable with Zevra's commercial rare-disease franchise.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

IRWD

Similar market capitalization and a commercial pharmaceutical business, but a different therapeutic area; only a loose valuation comparison.

AVTX

Similar market capitalization, but its development-stage profile is not directly comparable with Zevra's commercial rare-disease franchise.